FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2220367114> ?p ?o ?g. }

• W2220367114 endingPage "S32" @default.
• W2220367114 startingPage "S32" @default.
• W2220367114 abstract "BackgroundIn China, more than 10% of individuals infected with HIV are carriers of hepatitis B virus (HBV). Patients infected with HIV-1 are usually given combination antiretroviral therapy that includes lamivudine (ART-3TC) as a reverse-transcriptase inhibitor. Previous studies from some developed counties showed that, in ART-3TC, 3TC-resistant HBV progressively emerges at a rate of 15–20% per year in patients co-infected with HIV-1 and HBV. We investigated the occurrence of 3TC-resistant HBV during ART-3TC for double infections and tested the use of tenofovir disoproxil fumarate (TDF) as an additional reverse-transcriptase inhibitor (ART-3TC/TDF) in a 2-year cohort study in China.Methods172 plasma samples from 43 Chinese patients co-infected with HIV-1 and HBV (from 134 cases positive for HBsAg) were examined for the prevalence of 3TC-resistant HBV by direct sequencing of PCR products covering the HBV reverse transcriptase gene. The patients were randomised (7:1), using a randomised number table, to receive either ART-3TC or ART-3TC/TDF (because ART-3TC/TDF was not a standard first-line treatment in China at that time). HIV-1 RNA and HBV DNA loads were detected at baseline, 12 weeks, 48 weeks, and 96 weeks from plasma samples. All samples were tested for HIV and HBV drug resistance against 3TC. The efficacy of viral suppression and incidence of drug-resistance mutation were compared between the two groups. This study was approved by the ethics committee at Peking Union Medical College Hospital, Beijing, China, and registered at ClinicalTrials.gov (identifiers NCT00618176 and NCT00872417). Patients were enrolled in Chinese cohort studies (National Key Technologies R&D Program for the tenth and 11th Five-year Plans).FindingsMedian HIV-1 RNA loads of the ART-3TC group and the ART-3TC/TDF group significantly decreased from 26 205 copies/mL (IQR 917; p<0·0001) to fewer than 20 copies/mL (<20; p=0·0278) and from 58 972 copies/mL (3395; p<0·0001) to fewer than 20 copies/mL (<20; p=0·0207), respectively, after 96 weeks of treatment. Median HBV DNA loads also significantly decreased from 3·4 × 106 IU/mL (IQR <20; p<0·0001) to less than 20 IU/mL (<20; p<0·0001) in the ART-3TC group and from 2·7×105 IU/mL (399; p<0·;0001) to less than 20 IU/mL (<20; p=0·0152) in the ART-3TC/TDF group after 96 weeks of treatment. Although median HIV-1 viral load did not differ significantly (p>0·05) between the two groups after 96 weeks, the rate of HIV-1 RNA decline in the ART-3TC/TDF group was slightly lower than that in the ART-3TC group (RNA load range <20–905 copies/mL vs <20–4932 copies/mL at 12 weeks, <20–157 copies/mL vs <20–398 copies/mL at 48 weeks). ART-3TC/TDF had a higher efficacy than ART-3TC in controlling amounts of HBV. At 96 weeks, the median HBV DNA load was less than 20 IU/mL (IQR <20–1·2 × 108) in the ART-3TC group, suggesting that some patients had rebound or uncontrolled HBV DNA loads, but no such case was reported in the ART-3TC/TDF group, the median HBV DNA load of which was <20 IU/mL (<20; p=0<0119). Ten (23%) of 43 patients, all from the ART-3TC group, had HBV breakthrough after 96 weeks of treatment, and eight of these patients were resistant to ART-3TC (60% tr204 mutation and 80% rt180 mutation; appendix).InterpretationAlthough both regimens were able to control replication of HIV and HBV during the 2-year treatment, our findings showed that, in China, ART-3TC is likely to lead to the emergence of 3TC-resistant HBV, lending support to the benefit of the inclusion of TDF for patients co-infected with HIV-1 and HBV." @default.
• W2220367114 created "2016-06-24" @default.
• W2220367114 creator A5009902616 @default.
• W2220367114 creator A5031880803 @default.
• W2220367114 creator A5031998757 @default.
• W2220367114 creator A5044459845 @default.
• W2220367114 creator A5051817115 @default.
• W2220367114 creator A5073548335 @default.
• W2220367114 creator A5075051424 @default.
• W2220367114 creator A5075673227 @default.
• W2220367114 creator A5084027922 @default.
• W2220367114 creator A5091848154 @default.
• W2220367114 date "2015-10-01" @default.
• W2220367114 modified "2023-09-26" @default.
• W2220367114 title "Emergence of lamivudine-resistant hepatitis B virus during combination antiretroviral therapy that includes lamivudine for patients co-infected with HIV and hepatitis B virus in China: a 2-year pilot cohort study" @default.
• W2220367114 doi "https://doi.org/10.1016/s0140-6736(15)00613-3" @default.
• W2220367114 hasPublicationYear "2015" @default.
• W2220367114 type Work @default.
• W2220367114 sameAs 2220367114 @default.
• W2220367114 citedByCount "0" @default.
• W2220367114 crossrefType "journal-article" @default.
• W2220367114 hasAuthorship W2220367114A5009902616 @default.
• W2220367114 hasAuthorship W2220367114A5031880803 @default.
• W2220367114 hasAuthorship W2220367114A5031998757 @default.
• W2220367114 hasAuthorship W2220367114A5044459845 @default.
• W2220367114 hasAuthorship W2220367114A5051817115 @default.
• W2220367114 hasAuthorship W2220367114A5073548335 @default.
• W2220367114 hasAuthorship W2220367114A5075051424 @default.
• W2220367114 hasAuthorship W2220367114A5075673227 @default.
• W2220367114 hasAuthorship W2220367114A5084027922 @default.
• W2220367114 hasAuthorship W2220367114A5091848154 @default.
• W2220367114 hasBestOaLocation W22203671141 @default.
• W2220367114 hasConcept C114851261 @default.
• W2220367114 hasConcept C126322002 @default.
• W2220367114 hasConcept C142462285 @default.
• W2220367114 hasConcept C159047783 @default.
• W2220367114 hasConcept C2522874641 @default.
• W2220367114 hasConcept C2777351918 @default.
• W2220367114 hasConcept C2777382497 @default.
• W2220367114 hasConcept C2777410769 @default.
• W2220367114 hasConcept C2777869810 @default.
• W2220367114 hasConcept C2780593183 @default.
• W2220367114 hasConcept C2993143319 @default.
• W2220367114 hasConcept C71924100 @default.
• W2220367114 hasConcept C86803240 @default.
• W2220367114 hasConcept C89423630 @default.
• W2220367114 hasConceptScore W2220367114C114851261 @default.
• W2220367114 hasConceptScore W2220367114C126322002 @default.
• W2220367114 hasConceptScore W2220367114C142462285 @default.
• W2220367114 hasConceptScore W2220367114C159047783 @default.
• W2220367114 hasConceptScore W2220367114C2522874641 @default.
• W2220367114 hasConceptScore W2220367114C2777351918 @default.
• W2220367114 hasConceptScore W2220367114C2777382497 @default.
• W2220367114 hasConceptScore W2220367114C2777410769 @default.
• W2220367114 hasConceptScore W2220367114C2777869810 @default.
• W2220367114 hasConceptScore W2220367114C2780593183 @default.
• W2220367114 hasConceptScore W2220367114C2993143319 @default.
• W2220367114 hasConceptScore W2220367114C71924100 @default.
• W2220367114 hasConceptScore W2220367114C86803240 @default.
• W2220367114 hasConceptScore W2220367114C89423630 @default.
• W2220367114 hasLocation W22203671141 @default.
• W2220367114 hasOpenAccess W2220367114 @default.
• W2220367114 hasPrimaryLocation W22203671141 @default.
• W2220367114 hasRelatedWork W2021761678 @default.
• W2220367114 hasRelatedWork W2029205763 @default.
• W2220367114 hasRelatedWork W2046622424 @default.
• W2220367114 hasRelatedWork W2053051468 @default.
• W2220367114 hasRelatedWork W2095500893 @default.
• W2220367114 hasRelatedWork W2125489884 @default.
• W2220367114 hasRelatedWork W2327827871 @default.
• W2220367114 hasRelatedWork W2956118677 @default.
• W2220367114 hasRelatedWork W2979056921 @default.
• W2220367114 hasRelatedWork W3111586912 @default.
• W2220367114 hasVolume "386" @default.
• W2220367114 isParatext "false" @default.
• W2220367114 isRetracted "false" @default.
• W2220367114 magId "2220367114" @default.
• W2220367114 workType "article" @default.